

# Pharmerit Staff Publications by Service Area



# 1 Economic Modeling

Kay G, Eby EL, Brown B, Lyon J, Eggington S, Kumar G, **Fenwick E**, Sohail MR, Wright DJ. Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection. *Journal of Medical Economics*. 2018. 21:3, 294-300, DOI: 10.1080/13696998.2017.1409227

Shi G, Park SH, Ren H, Xue M, Lu X, Dong P, **Gao X**. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. *J Med Econ*. 2018 Sep 10:1-9. doi: 10.1080/13696998.2018.1515769. [Epub ahead of print]

Tremblay G, Howard D, Tsong W, **Patel V**, De Rosendo J. Cost-effectiveness of peramppanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective. *Epilepsy Behav*. 2018 Sep;86:108-115. doi: 10.1016/j.yebeh.2018.06.002. Epub 2018 Jul 9.

**Botteman MF, Bhanegaonkar AJ, Horodniceanu EG**, Ji X, Lee BW, Shek LP, Van Bever HP, Detzel P. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk, not exclusively breastfed infants in Singapore. *Singapore medical journal*. 2018 Aug;59(8):439.

**Piena MA, Heisen M**, Wormhoudt LW, van Wingerden J, Frequin STFM, Uitdehaag BMJ. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands. *J Med Econ*. 2018 Jun 18:1-16. doi: 10.1080/13696998.2018.1489255. [Epub ahead of print]

Shelbaya A, **Solem CT**, Walker C, **Wan Y**, Johnson C, Cappelleri JC. The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis. *Clinicoecon. Outcomes Res*. 2018 Apr 6;10:213-222. doi: 10.2147/CEOR.S140208. eCollection 2018.

McKinnell JA, **Corman S, Patel D**, Leung GH, Gordon LM, Lodise TP. Effective antimicrobial stewardship strategies for cost-effective utilization of Telavancin for the treatment of patients with hospital-acquired bacterial pneumonia caused by staphylococcus aureus. *Clin. Ther*. 2018 Mar.40(3):406-414.e2. doi: 10.1016/j.clinthera.2018.01.010. Epub 2018 Feb 15.

**Schmidt R, Majer I**, García Román N, Rivas Basterra A, Grubb E, Medrano López C. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. *Health Econ Rev*. 2017 Dec 19;7(1):47. doi: 10.1186/s13561-017-0181-3.

**Klijn SL**, van den Reek JMPA, van de **Wetering G**, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. *Br J Dermatol*. 2018 May;178(5):1181-1189. doi: 10.1111/bjd.16247. Epub 2018 Mar 1.

**Botteman MF**, Bhanegaonkar AJ, **Horodniceanu EG**, Ji X, Lee BW, Shek LP, Van Bever HP, Detzel P. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk infants not exclusively breastfed in Singapore. *Singapore Med J*. 2018 Aug;59(8):439-448. doi: 10.11622/smedj.2017113. Epub 2017 Dec 7.



Naylor NR, Uchegbu I, **Chatterjee A**, Robotham JV. Gambling with antibiotics: a novel approach for exploring antibiotic consumption decision-making. *Public Health*. 2017 Oct;151:146-148. doi: 10.1016/j.puhe.2017.07.012. Epub 2017 Aug 9.

Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, **van Hout B**, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. *JAMA Cardiol*. 2017 Oct 1;2(10):1069-1078. doi: 10.1001/jamacardio.2017.2762.

**Corman S**, Elbasha EH, **Michalopoulos SN**, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. *Value Health*. 2017 Sep;20(8):1110-1120. doi: 10.1016/j.jval.2017.05.003. Epub 2017 Jun 20.

Aletaha D, **Snedecor SJ**, **Ektare V**, **Xue M**, **Bao Y**, Garg V. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor- $\alpha$  inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. *Clinicoecon Outcomes Res*. 2017 Jul 28;9:451-458. doi: 10.2147/CEOR.S136327. eCollection 2017.

**Heisen M**, **Treur MJ**, Heemstra HE, Giesen EBW, Postma MJ. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. *J Med Econ*. 2017 Jun 25:1-12. doi: 10.1080/13696998.2017.1331912.

Flannery K, Drea E, Hudspeth L, **Corman S**, **Gao X**, **Xue M**, Miao R. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer. *J Manag Care Spec Pharm*. 2017 Apr;23(4):416-426. doi: 10.18553/jmcp.2017.23.4.416.

Drummond M, **Houwing N**, Slothuus U, Giangrande P. Making economic evaluations more helpful for treatment choices in haemophilia. *Haemophilia*. 2017 Mar;23(2):e58-e66. doi: 10.1111/hae.13173. Review.

Tremblay G, Barghout V, **Patel V**, Tsong W, Wang Z. Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United States. *Epilepsy Behav*. 2017 Mar 6;68:196-202. doi: 10.1016/j.yebeh.2016.12.029.

**Westerhout KY**, **Bouwmeester W**, Duchesne I, Pisini M, **Piana MA**, Damele F, Gueron B, **Treur M**, Belsey J. Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. *Clinicoecon Outcomes Res*. 2017 Feb 27;9:163-172. doi: 10.2147/CEOR.S117650.

**Bennison C**, **Stephens S**, Lescauwaet B, **Van Hout B**, Jackson TL. Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole. *J Mark Access Health Policy*. 2016 Jun;4. doi: 10.3402/jmahp.v4.31472. eCollection 2016.

**Chuang LH**, **Verheggen BG**, **Charokopou M**, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. *J Med Econ*. 2016 Jun:1-8.

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, **van Hout B**. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. *Clin Cardiol*. 2016 Jun;39(6):313-20. doi: 10.1002/clc.22535.



Mercer SW, Fitzpatrick B, Guthrie B, **Fenwick E**, Grieve E, Lawson K, Boyer N, McConnachie A, Lloyd SM, O'Brien R, Watt GCM, Wyke S. The CARE Plus study – a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised trial and cost-utility analysis. *BMC Medicine*. 2016. 14:88.

Mao N, **Leshner B**, Liu Q, **Qin L**, Chen Y, **Gao X**, Earnshaw SR, McDade CL, Charbonneau C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. *Clinicoecon Outcomes Res*. 2016 Jun 14;8:275-85. doi: 10.2147/CEOR.S101015. eCollection 2016.

Rello J, Nieto M, Solé-Violán J, **Wan Y**, **Gao X**, **Solem CT**, De Salas-Cansado M, Mesa F, Charbonneau C, Chastre J. Nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective. *Med Intensiva*. 2016 Apr 6. pii: S0210-5691(16)00045-0. doi: 10.1016/j.medin.2016.01.007

Angulo JC, Sánchez-Ballester F, Peral C, Rejas J, Ramos J, **Snedecor SJ**, **Sudharshan L**, **Liu S**, Luo X. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. *Actas Urol Esp*. 2016 Mar 14. pii: S0210-4806(16)00045-0. doi: 10.1016/j.acuro.2015.11.012.

**Qin L**, Luo X, Zou KH, **Snedecor SJ**. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States. *J Med Econ*. 2016 Mar;19(3):229-35. doi: 10.3111/13696998.2015.1111893.

**Charokopou M**. Using health economic models to help guide healthcare decisions. *Curr Med Res Opin*. 2016 Feb;32(2):205-6. doi: 10.1185/03007995.2015.1102721

Corbacho B, Duarte A, Keding A, Handoll H, **Chuang LH**, Torgerson D, Brealey S, Jefferson L, Hewitt C, Rangan A. Cost effectiveness of surgical versus non-surgical treatment of adults with displaced fractures of the proximal humerus: economic evaluation alongside the PROFHER trial. *Bone Joint J*. 2016 Feb;98-B(2):152-9.

**Wan Y**, Li Q, Chen Y, Haider S, **Liu S**, **Gao X**. Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study. *J Med Econ*. 2016 Jan;19(1):53-62. Doi: 10.3111/13696998.2015.1088448.

**Ektare V**, **Khachatryan A**, **Xue M**, Dunne M, Johnson K, **Stephens J**. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. *J Med Econ*. 2015 Dec;18(12):1092-101. doi: 10.3111/13696998.2015.1078339

**Tempest M**, Sapin C, Beillat M, Robinson P, **Treur M**. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. *J Ment Health Policy Econ*. 2015 Dec;18(4):185-200.

Mohiuddin S, Payne K, **Fenwick E**, O'Brien K, Bruce I. A model-based cost-effectiveness analysis of a grommets-led care pathway for children with cleft palate affected by otitis media with effusion. *The European Journal of Health Economics*. 2015, 16 (6): 573-587.



**Charokopou M**, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, **Postema R**, Townsend R, Roudaut M. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. *BMC Health Serv Res*. 2015 Nov 5;15(1):496. doi: 10.1186/s12913-015-1139-y.

Zeidan AM, Mahmoud D, **Kucmin-Bemelmans IT**, **Alleman CJ**, **Hensen M**, Skikne B, Smith BD. Economic burden associated with acute myeloid leukemia treatment. *Expert Rev Hematol*. 2015 Nov 14:1-11.

Pierotti F, Palla I, **Treur M**, Pippo L, Turchetti G. Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-effectiveness Analysis. *PLoS One*. 2015 Oct; 10(10):e0140843. doi: 10.1371/journal.pone.0140843.

**Begum N**, **Stephens S**, **Schoeman O**, Frascchke A, Kirsch B, Briere JB, Verheugt FW, **van Hout BA**. Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. *Cardiol Ther*. 2015 Dec;4(2):131-53.

**Stephens S**, **Botteman MF**, Cifaldi MA, **van Hout BA**. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. *BMJ Open*. 2015 Jun; 9;5(6):e006560. doi: 10.1136/bmjopen-2014-006560.

Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A, **Van Hout B**. The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. *Value Health*. 2015 Jun;18(4):376-86. doi: 10.1016/j.jval.2015.04.002.

**Bhanegaonkar A**, **Horodniceanu EG**, **Ji X**, Detzel P, Boguniewicz M, Chamlin S, Lake A, Czerkies LA, **Botteman MF**, Saavedra JM. Economic Burden of Atopic Dermatitis in High-Risk Infants Receiving Cow's Milk or Partially Hydrolyzed 100% Whey-Based Formula. *J Pediatr*. 2015 May; 166(5):1145-1151.e3.

**Bhanegaonkar AJ**, **Horodniceanu EG**, Abdul Latiff AH, Woodhull S, Khoo PC, Detzel P, **Ji X**, **Botteman MF**. Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants. *Asia Pac Allergy*. 2015 Apr;5(2):84-97.

**Botteman M**, Detzel P. Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in high-risk urban infants in Southeast Asia. *Ann Nutr Metab*. 2015; 66 Suppl 1:26-32. doi: 10.1159/000370222. Epub 2015 Apr 24.

**Charokopou M**, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, **Postema R**, Townsend R, Roudaut M. The effect of health state selection on the valuation of EQ-5D Type 2 diabetes mellitus. *Diabet Med*. 2015 Jul; 32(7):890-8. doi: 10.1111/dme.12772. Epub 2015 Apr.

Westerhout K, **Treur M**, Mehnert A, Pascoe K, Ladha I, Belsey J. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. *J Med Econ*. 2015 Apr 23; 1-19.

Handoll H, Brealey S, Rangan A, Keding A, Corbacho B, Jefferson L, **Chuang LH**, Goodchild L, Hewitt C, Torgerson D. The ProFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial - a pragmatic multicentre randomised controlled trial evaluating the clinical effectiveness and cost-effectiveness of surgical compared with non-surgical treatment for proximal fracture of the humerus in adults. *Health Technol Assess*. 2015 Mar; 19(24):1-280.



Wynants L, **Bouwmeester W**, Moons KG, Moerbeek M, Timmerman D, Van Huffel S, Van Calster B, Vergouwe Y. A simulation study of sample size demonstrated the importance of the number of events per variable to develop prediction models in clustered data. *J Clin Epidemiol*. 2015 Dec;68(12):1406-14. doi: 10.1016/j.jclinepi.2015.02.002. Epub 2015 Feb 14.

Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin N, **Fenwick E**, Goldberg D. Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques. *PLoS One*. 2015. 10 (12).

**Verheggen BG**, **Westerhout KY**, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. *Clin Transl Allergy*. 2015 Jan; 21;5:1. doi: 10.1186/s13601-015-0045-z. eCollection 2015.

Kuwabara H, Westerhout K, **Treur M**, Cerri K, Mahlich J, Yatsunami H. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. *J Med Econ*. 2015;18(7):502-11.

Liu FX, Ghaffari A, **Dhatt H**, Kumar V, Balsara C, Wallace E, Khairullah Q, **Leshner B**, **Gao X**, Henderson H, LaFleur P, Delgado EM, Alvarez MM, Hartley J, McClernon M, Walton S, Guest S. Economic evaluation of urgent-start peritoneal dialysis versus urgent-start hemodialysis in the United States. *Medicine (Baltimore)*. 2014 Dec; 93(28):e293. doi: 10.1097/MD.0000000000000293.

**Ektare VU**, Lopez JM, Martin SC, **Patel DA**, Rupnow MF, **Botteman MF**. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. *Am J Manag Care*. 2014 Oct; 20(10 Suppl):S204-15.

Keeping ST, **Tempest MJ**, **Stephens SJ**, **Carroll SM**, Nugent KP, O'Dwyer ST. The cost of anal cancer in England: retrospective hospital data analysis and Markov model. *BMC Public Health*. 2014 Oct 31; 14:1123. doi: 10.1186/1471-2458-14-1123.

**Patel DA**, Michel A, **Stephens J**, Weber B, Petrik C, Charbonneau C. An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia in Germany. *Infect Drug Resist*. 2014 Oct 24; 7:273-80. doi: 10.2147/IDR.S68658. eCollection 2014.

Villa G, Lothgren M, Gandra SR, Lindgren P, **van Hout B**. Deterministic Versus Stochastic Prediction of Risk for Cardiovascular Events. *Value Health*. 2014 Nov;17(7):A558. doi: 10.1016/j.jval.2014.08.1840. Epub 2014 Oct 26.

**Patel V**, **Lin FJ**, Ojo O, Rao S, Yu S, Zhan L, Touchette DR. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. *Pharm Pract (Granada)*. 2014 Jul; 12(3):438. Epub 2014 Sep 4.

Ostermann H, Solano C, Jarque I, Garcia-Vidal C, **Gao X**, Barrueta JA, De Salas-Cansado M, **Stephens J**, **Xue M**, Weber B, Charbonneau C. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. *BMC Pharmacol Toxicol*. 2014 Sep 24; 15:52. doi: 10.1186/2050-6511-15-52.

Niedermaier MS, Chastre J, **Solem CT**, **Wan Y**, **Gao X**, Myers DE, Haider S, Li JZ, **Stephens JM**. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus*: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. *Clin Ther*. 2014 Sep 1;36(9):1233-1243.e1. doi: 10.1016/j.clinthera.2014.06.029. Epub 2014 Jul 25.



Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, Chen C, Hajek P, **Patel DA**, **Gao X**. Cost-Effectiveness of Linezolid versus Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Confirmed Nosocomial Pneumonia in China. May 2014; doi:10.1016/j.vhri.2014.03.002.

Stevanović J, O'Prinsen AC, **Verheggen BG**, Schuiling-Veninga N, Postma MJ, Pechlivanoglou P. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Clin Ther. 2014 Mar 1; 36(3):368-84.e5.

**Heeg BM**, **van Hout BA**. Assessing uncertainties surrounding combined endpoints for use in economic models. Med Decis Making. 2014 Apr; 34(3):300-10.

**Bennison C**, **Stephens S**., Conti, GN,. Cost-effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non-Muscle Invasive Bladder Cancer patients (NMIBC) in Italy. 2014; Doi: <http://dx.doi.org/10.7175/fe.v15i3.944>.

Liu X, **Botteman M**, **Patel D**, DeLegge M, Mercaldi C and Turpin R. Cost Effectiveness Analysis of Parenteral Nutrition Therapies among Hospitalized Patients: Multi-chamber Bag System vs. Compounding. Int. J. of Healthcare Technology and Management 2014; Vol.14, No.3 pp.176 – 193.

**Majer IM**, Gelderblom H, van den Hout WB, Gray E, **Verheggen BG**. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. J Med Econ. 2013 Sep; 16(9):1106-19.

Murphy A, **Fenwick E**, Neilson MP, Toff WD, Berry C, Uren NG, Oldroyd KG, Briggs AH. Transcatheter-Aortic-Valve-Replacement for severe aortic stenosis: Cost-effectiveness for inoperable UK patients. International Journal of Technology Assessment in Health Care. 2013, 29 (1): 1-8.

**Stephens JM**, **Gao X**, **Patel DA**, **Verheggen BG**, Shelbaya A, Haider S. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013 Sep 16; 5:447-57.

Mete Saylan, **M.J. Treur**, R. Postema, N. Dilbaz, H. Savas, B.M. Heeg, P.B. Drost. Cost-effectiveness analysis of aripiprazole augmentation treatment of major depressive disorder patients compared to olanzapine and quetiapine augmentation in Turkey; a micro-simulation approach. Science Direct. 2013 August. doi:10.1016/j.vhri.2013.06.004

Tong WH, van der Sluis IM, **Alleman C**, van Litsenburg RR, Kaspers G, Pieters R and Uyl-de Groot CA. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica. 2013 May; 98(5):753-9.

**Majer IM**, Stevens R, Nusselder WJ, Mackenbach JP and van Baal PH. Modeling and forecasting health expectancy: theoretical framework and application. Demography. 2013 Apr; 50(2):673-97.

**Snedecor SJ**, **Carter JA**, Kaura S, **Botteman MF**. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ. 2013; 16(1):19-29.

de Meijer CA, **Majer IM**, Koopmanschap MA and van Baal PH. Forecasting lifetime and aggregate long-term care spending: accounting for changing disability patterns. Med Care. 2012 Aug;50(8):722-9.



**Snedecor SJ, Carter JA, Kaura S, Botteman MF.** Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. *Clin Ther.* 2012 Jun; 34(6):1334-49.

Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ and **van Hout BA.** Cost-effectiveness of additional blood screening tests in the Netherlands. *Transfusion.* 2012 Mar; 52(3):478-88.

Cohen DJ, Lavelle TA, **Van Hout B,** Li H, Lei Y, Robertus K, Pinto D, Magnuson EA, McGarry TF, Lucas SK, Horwitz PA, Henry CA, Serruys PW, Mohr FW and Kappetein AP. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. *Catheter Cardiovasc Interv.* 2012 Feb;79(2):198-209.

**Heisen M, Treur MJ,** van der Hel WS, Frequin ST, Groot MT, **Verheggen BG.** Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands. *J Med Econ.* 2012; 15(6):1149-58.

**Westerhout KY, Verheggen BG,** Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. *J Med Econ.* 2012; 15(5):906-17.

**Treur M,** Baca E, Bobes J, Cañas F, Salvador L, Gonzalez B, **Heeg B.** The cost-effectiveness of paliperidone extended release in Spain. *J Med Econ.* 2012; 15 Suppl 1:26-34. doi: 10.3111/13696998.2012.734884. Epub 2012 Oct 23.

**Verheggen BG,** Lee R, Lieu On MM, **Treur MJ, Botteman MF,** Kaplan SA and Trocio JN. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder. *J Med Econ.* 2012; 15(3):586-600.

**Botteman MF,** Meijboom M, Foley I, **Stephens JM,** Chen YM, Kaura S. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. *Eur J Health Econ.* 2011 Dec; 12(6):575-88.

**Heemstra HE,** Nieuwlaat R, **Meijboom M,** Crijns HJ. The burden of atrial fibrillation in the Netherlands. *Neth Heart J.* 2011 Sep; 19(9):373-8.

Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM and **van Hout BA.** A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. *Haematologica.* 2011 May; 96(5):738-43.

Thureson PO, **Heeg B,** Lescauwat B, Sennfalt K, Alaeus A, Neubauer A. Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. *Scand J Infect Dis.* 2011 Apr; 43(4):304-12.

Joshi AD, **Carter JA, Botteman MF,** Kaura S. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom. *Clin Ther.* 2011 Mar; 33(3):291-304.e8.

Watson JM, Kang'ombe AR, Soares MO, **Chuang LH,** Worthy G, Bland JM, Iglesias C, Cullum N, Torgerson D, Nelson EA and Ven USIII. VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers. *Health Technol Assess.* 2011 Mar; 15(13):1-192.





**Carter JA**, Joshi A, Kaura S, **Botteman MF**. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. *J Med Econ*. 2011; 14(3):288-98.

**Chuang LH**, Soares MO, Watson JM, Bland JM, Cullum N, Iglesias C, Kang'ombe AR, Torgerson D, Nelson EA and Ven USIII. Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers. *Br J Surg*. 2011; 98(8):1099-106.

**Majer IM**, Nusselder WJ, Mackenbach JP and Kunst AE. Socioeconomic inequalities in life and health expectancies around official retirement age in 10 Western-European countries. *J Epidemiol Community Health*. 2011; 65(11):972-9.

Idema WJ, **Majer IM**, Pahan D, Oskam L, Polinder S and Richardus JH. Cost-effectiveness of a chemoprophylactic intervention with single dose rifampicin in contacts of new leprosy patients. *PLoS Negl Trop Dis*. 2010 Nov 2; 4(11):e874. doi: 10.1371/journal.pntd.0000874.

**Heisen M**, Fan X, Buurman J, van Riel NA, Karczmar GS and ter Haar Romeny BM. The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI data. *Phys Med Biol*. 2010 Aug;55(16):4871-83.

Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, **van Hout BA**. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. *Vox Sang*. 2010 Jul; 99(1):54-64.

Logman JF, **Heeg BM**, **Botteman MF**, Kaura S, **van Hout BA**. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. *Ann Oncol*. 2010 Jul; 21(7):1529-36.

Wassenberg MW, de Wit GA, **van Hout BA**, Bonten MJ. Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA. *PLoS One*. 2010 Jul; 5(7):e11562.

**Heisen M**, Fan X, Buurman J, van Riel NA, Karczmar GS and ter Haar Romeny BM. The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. *Magn Reson Med*. 2010 Mar;63(3):811-6.

Thurston SJ, **Heeg B**, de Charro F, **van Hout B**. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial. *Curr Med Res Opin*. 2010 Mar; 26(3): 641-651

**Hensen M**, **Heeg B**, Löthgren M, **van Hout B**. Cost effectiveness of long-acting risperidone in Sweden. *Appl Health Econ Health Policy*. 2010;8(5):327-41

Logman JF, **Heeg BM**, Herlitz J, **van Hout BA**. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. *Appl Health Econ Health Policy*. 2010; 8(4):251-65.

Logman JF, **Heeg BM**, **Botteman MF**, Kaura S, **van Hout BA**. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. *Ann Oncol*. 2010 Jul;21(7):1529-36. doi: 10.1093/annonc/mdp560. Epub 2009 Dec 2.



**Snedecor SJ, Botteman MF**, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. *Sleep*. 2009 Jun;32(6):817-24.

**Snedecor SJ**, Strutton DR, Ciuryla V, Schwartz EJ, **Botteman MF**. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. *Vaccine*. 2009 Jul 23;27(34):4694-703. doi: 10.1016/j.vaccine.2009.05.062. Epub 2009 Jun 9.

**Treur M, Heeg B**, Möller HJ, Schmeding A, **van Hout B**. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. *BMC Health Serv Res*. 2009 Feb 18;9:32. doi: 10.1186/1472-6963-9-32.

**Heeg BM**, Damen J, Buskens E, Caleo S, de Charro F, **van Hout BA**. Modelling approaches: the case of schizophrenia. *Pharmacoeconomics*. 2008;26(8):633-48.

**Heeg B**, Buskens E, **Botteman M**, Caleo S, Ingham M, Damen J, de Charro F, **van Hout B**. The cost-effectiveness of atypicals in the UK. *Value Health*. 2008 Dec;11(7):1007-21. doi: 10.1111/j.1524-4733.2008.00344.x. Epub 2008 May 16.

Damen J, Thuresson PO, **Heeg B**, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. *Appl Health Econ Health Policy*. 2008;6(4):189-97. doi: 10.2165/00148365-200806040-00002

**Heeg BM**, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, **Van Hout BA**. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. *Curr Med Res Opin*. 2008 Feb;24(2):349-58

Carpniuc KT, **Stephens JM, Botteman MF**, Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Expert Opin Pharmacother*. 2007 Nov;8(16):2775-87

**Heeg BM**, Peters RJ, **Botteman M, van Hout BA**. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. *Pharmacoeconomics*. 2007;25(9):769-82.

**Botteman MF**, Hay JW, Luo MP, Curry AS, Wong RL, **van Hout BA**. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. *Rheumatology (Oxford)*. 2007 Aug;46(8):1320-8. Epub 2007 Jun 2.

**Botteman MF**, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. *CNS Drugs*. 2007;21(4):319-34.

**Heeg B**, van Gestel A, **van Hout BA**, Olsen J, Haghfelt TH. [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark]. *Ugeskr Laeger*. 2006 Aug 28;168(35):2911-5.

**Botteman M**, Barghout V, **Stephens J**, Hay J, Brandman J, Aapro M. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. *Ann Oncol*. 2006 Jul;17(7):1072-82. Epub 2006 May 2.

Buskens E, Meijboom MJ, Kooijman H, **Van Hout BA**. The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysis. *J Cardiovasc Surg (Torino)*. 2006 Apr;47(2):161-70.



[Heeg B](#), Buskens E, Knapp M, van Aalst G, Dries PJ, de Haan L, [van Hout BA](#). Modelling the treated course of schizophrenia: development of a discrete event simulation model. *Pharmacoeconomics*. 2005;23 Suppl 1:17-33.



## 2 Literature Review

Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, [Chatterjee A](#), Knight GM, Robotham JV. Estimating the burden of antimicrobial resistance: a systematic literature review. *Antimicrob Resist Infect Control*. 2018 Apr 25;7:58. doi: 10.1186/s13756-018-0336-y. eCollection 2018.

[Chatterjee A](#), Modarai M, Naylor NR, Boyd SE3, Atun R, Barlow J, Holmes AH, Johnson A, Robotham JV. Quantifying drivers of antibiotic resistance in humans: a systematic review. *Lancet Infect Dis*. 2018 Aug 29. pii: S1473-3099(18)30296-2. doi: 10.1016/S1473-3099(18)30296-2. [Epub ahead of print]

[Snedecor SJ](#). Review of Economic Value Drivers of the Treatment of Overactive Bladder. *Pharmacoeconomics*. 2018 May 4. doi: 10.1007/s40273-018-0663-0.

[Tieu C](#), [Lucas EJ](#), DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products : A systematic review. *PLoS One*. 2018 Apr 18;13(4):e0195012. doi: 10.1371/journal.pone.0195012. eCollection 2018.

[Solem CT](#), Kwon Y, [Shah RM](#), [Aly A](#), [Botteman MF](#). Systematic review and benchmarking of quality-adjusted time without symptoms or toxicity (Q-TWIST) in oncology. *Expert Rev Pharmacoecon Outcomes Res*. 2018 Jun;18(3):245-253. doi: 10.1080/14737167.2018.1434414. Epub 2018 Feb 5.

Schmidt HH, Waddington-Cruz M, [Botteman MF](#), Carter JA, [Chopra AS](#), Hopps M, Stewart M, Fallet S, Amass L. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. *Muscle Nerve*. 2018 May;57(5):829-837. doi: 10.1002/mus.26034. Epub 2018 Feb 1.

Ijzerman MJ, Koffijberg H, [Fenwick E](#), Krahn M. Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. *Pharmacoeconomics*. 2017.

Cooke CE, [Stephens JM](#). Clinical, economic, and humanistic burden of needlestick injuries in healthcare workers. *Med Devices (Auckl)*. 2017 Sep 29;10:225-235. doi: 10.2147/MDER.S140846.

Lishman H, Aylin P, Alividza V, Castro-Sanchez E, [Chatterjee A](#), Mariano V, Johnson AP, Jeraj S, Costelloe C. Investigating the burden of antibiotic resistance in ethnic minority groups in high-income countries: protocol for a systematic review and meta-analysis. *Syst Rev*. 2017 Dec 11;6(1):251. doi: 10.1186/s13643-017-0654-9.

Lin HM, [Gao X](#), [Cooke CE](#), Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. *Curr Med Res Opin*. 2017 Jun;33(6):1017-1031. doi: 10.1080/03007995.2017.1297930.

van Nooten F, [Treur M](#), [Pantiri K](#), Stoker M, [Charokopou M](#). Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis. *Clin Ther*. 2017 Apr;39(4):787-803.e18. doi: 10.1016/j.clinthera.2017.02.010.



Cruz MW, Schmidt H, **Botteman MF**, **Carter JA**, **Chopra AS**, Stewart M, Hopps M, Fallet S, Amass L. Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases. *Amyloid*. 2017 Mar;24(sup1):109-110. doi: 10.1080/13506129.2017.1292902.

Schmidt H, Cruz MW, **Botteman MF**, **Carter JA**, Chopra A, Stewart M, Hopps M, Fallet S, Amass L. Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review. *Amyloid*. 2017 Mar;24(sup1):111-112. doi: 10.1080/13506129.2017.1292903.

Joshi G, Gandhi K, **Shah N**, Gadsden J, **Corman S**. Peripheral nerve blocks in the management of postoperative pain: challenges and opportunities. *Journal of Clinical Anesthesia*. 2016 December; 35: 524–529. doi: 10.1016/j.jclinane.2016.08.041.

Lelli F, Nuhoho S, Lee XY, **Xu W**. Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. *Clin Exp Gastroenterol*. 2016;9:311-323. doi:10.2147/CEG.S109696.

**Ostawal A**, Mocevic E, Kragh N, **Xu W**. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. *Diabetes Ther*. 2016 Sep;7(3):411-38. doi: 10.1007/s13300-016-0180-0. Epub 2016 Jun 27. Review.

**Leshner B**, **Gao X**, Chen Y, Liu Z. Methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia: role of linezolid in the People's Republic of China. *Clinicoecon Outcomes Res*. 2016 Mar 24;8:63-72. doi: 10.2147/CEOR.S91985. eCollection 2016.

**Ektare V**, **Khachatryan A**, **Xue M**, Dunne M, Johnson K, **Stephens J**. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. *J Med Econ*. 2015 Dec;18(12):1092-101. doi: 10.3111/13696998.2015.1078339

McDonald M, **Patel DA**, Keith MS, **Snedecor SJ**. Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. *Ocul Surf*. 2015 Dec 27. pii: S1542-0124(15)00204-9

Schmid T, **Xu W**, Gandra SR, Michailov GV. Erratum to: 'Costs of treating cardiovascular events in Germany: a systematic literature review'. *Health Econ Rev*. 2015 Dec;6(1):1. doi: 10.1186/s13561-016-0080-z.

Zeidan AM, Mahmoud D, **Kucmin-Bemelmans IT**, **Alleman CJ**, **Hensen M**, Skikne B, Smith BD. Economic burden associated with acute myeloid leukemia treatment. *Expert Rev Hematol*. 2015 Nov 14:1-11.

**Charokopou M**, Sabater F, Townsend R, Roudaut M, McEwan P, Verheggen B. Methods applied in cost-effectiveness models for treatment strategies in Type 2 diabetes mellitus and their use in Health Technology Assessments; a systematic review of the literature from 2008 - 2013. *Curr Med Res Opin*. 2015 Oct 16:1-77.

Bartlett JD, Keith MS, **Sudharshan L**, **Snedecor SJ**. Associations between signs and symptoms of dry eye disease: a systematic review. *Clin Ophthalmol*. 2015 Sep 16;9:1719-30. doi: 10.2147/OPHTH.S89700.

Heller S, **Houwing N**, Kragh N, Ploug UJ, Nikolajsen A, **Alleman CJ**. Investigating the Evidence of the Real-Life Impact of Acute Hyperglycaemia. *Diabetes Ther*. 2015 Sep;6(3):389-93.

Moots RJ, **Mays R**, **Stephens J**, Tarallo M., Burden of dose escalation with tumour necrosis factor inhibitors in rheumatoid arthritis: a systematic review of frequency and costs., *Clin Exp Rheumatol*. 2015 Jun 8.



**Alleman CJ, Westerhout KY, Hensen M**, Chambers C, Stoker M, Long S, van Nooten FE., Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature., *Diabetes Res Clin Pract.* 2015 May 6.

Skledar SJ, **Corman SL**, Smitherman T., Addressing innovative off-label medication use at an academic medical center., *Am J Health Syst Pharm.* 2015 Mar 15;72(6):469-77.

**Patel DA, Snedecor SJ, Tang WY, Sudharshan L**, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, **Stephens J**, Nichols G., 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naïve HIV-1-infected patients: a systematic review and network meta-analysis. *PLoS One.* 2014 Sep;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014.

**de Jager T**, Pericleous L, Kokot-Kierepa M, Naderi M, Karimi M., The burden and management of FXIII deficiency. *Haemophilia.* 2014 Nov;20(6):733-40.

**Snedecor SJ, Sudharshan L**, Nedrow K, **Bhanegaonkar A**, Simpson KN, Haider S, Chambers R, Craig C, **Stephens J**., Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis., *AIDS Res Hum Retroviruses.* 2014 Aug;30(8):753-68.

**Snedecor SJ, Sudharshan L**, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, **Botteman M**., Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions., *Int J Clin Pract.* 2014 Jul;68(7):900-18.

Noens L, **Hensen M**, Kucmin-Bemelmans I, Lofgren C, Gilloteau I, Vrijens B. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. *Haematologica.* 2014 Mar;99(3):437-47. doi: 10.3324/haematol.2012.082511.

**Snedecor SJ, Sudharshan L**, Cappelleri JC, Sadosky A, **Mehta S, Botteman M**., Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy., *Pain Pract.* 2014 Feb;14(2):167-84.

Drgona L, **Khachatryan A, Stephens J**, Charbonneau C, Kantecki M, Haider S and Barnes R. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of *Aspergillus* and *Candida* species. *Eur J Clin Microbiol Infect Dis.* 2014 Jan; 33(1):7-21.

**Carter JA, Ji X, Botteman MF**. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. *Expert Rev Pharmacoecon Outcomes Res.* 2013 Aug;13(4):483-96.

**Snedecor SJ, Khachatryan A**, Nedrow K, Chambers R, Li C, Haider S, **Stephens J**. The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. *PLoS One.* 2013 Aug 22;8(8):e72784. doi: 10.1371/journal.pone.0072784.

**Snedecor SJ, Sudharshan L**, Cappelleri JC, Sadosky A, Desai P, Jalundhwala YJ, **Botteman M**., Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury., *J Pain Res.* 2013 Jul; 6:539-47.

Ganguli A, **Wiegand P, Gao X, Carter JA, Botteman MF** and Ray S. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. *Qual Life Res.* 2013 Jun;22(5):1015-26.



Grieve E, [Fenwick E](#), Yang H-C, Lean M. The disproportionate economic burden associated with severe and complicated obesity: a systematic review. 2013, 14 (11): 883-894.

Wu AW, Hanson KA, Harding G, Haider S, Tawadrous M, [Khachatryan A](#), Pashos CL and Simpson KN. Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. Health Qual Life Outcomes. 2013 Mar 12;11:42.

[Carter JA](#), [Botteman MF](#). Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):425-37.

[Gao X](#), [Stephens JM](#), [Carter JA](#), Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):335-43.

[Carter JA](#), Joshi AD, Kaura S, [Botteman MF](#). Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics. 2012 May;30(5):373-86.

[Wiegand PN](#), Nathwani D, Wilcox MH, [Stephens J](#), Shelbaya A, Haider S., Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection., J Hosp Infect. 2012 May;81(1):1-14.

[Gao X](#), Wendling D, [Botteman MF](#), [Carter JA](#), Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054-63.

[Xu W](#). Costs of treating cardiovascular diseases in Germany: A systematic literature review. Value in Health. 2012; 15:A368.

Ben-Shlomo A, Sheppard MC, [Stephens JM](#), Pulgar S and Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011 Sep;14(3):284-94.

[Majer IM](#), Nusselder WJ, Mackenbach JP and Kunst AE. Life expectancy and life expectancy with disability of normal weight, overweight, and obese smokers and nonsmokers in Europe. Obesity (Silver Spring). 2011 Jul;19(7):1451-9.

Terwee C.B., [Bouwmeester W.](#), van Elstrand S.L., de Vet H.C.W., Dekker J. , Instruments to assess physical activity in patients with osteoarthritis of the hip or knee: a systematic review of measurement properties, Osteoarthritis Cartilage. 2011 Jun;19(6):620-33. doi: 10.1016/j.joca.2011.01.002.

Scott JA, [Lasch KE](#), Barsevick AM and Piau-Louis E. Patients' experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol Nurs Forum. 2011 May;38(3):E191-203.

Logman JF, [Stephens J](#), [Heeg B](#), Haider S, Cappelleri J, Nathwani D, Tice A, [van Hout BA](#). Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections Current Medical Research & Opinion Vol. 26, No. 7, 2010, 1565–1578.

[Corman SL](#) and Mohammad RA. Eltrombopag: a novel oral thrombopoietin receptor agonist. Ann Pharmacother. 2010 Jun;44(6):1072-9.

[Stephens J](#), Carpiuc KT, [Botteman M](#). The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis. Int J Gen Med. 2010 Apr 8; 3:31-6.

Carpiuc KT, [Stephens JM](#), [Botteman MF](#), Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother. 2007 Nov;8(16):2775-87



**Stephens JM**, Joshi AV, Sumner M, **Botteman MF**. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. *Expert Opin Pharmacother*. 2007 Jun;8(8):1127-36.

Liou SY, **Stephens JM**, Carpiuc KT, Feng W, **Botteman MF**, Hay JW. Economic burden of haematological adverse effects in cancer patients: a systematic review. *Clin Drug Investig*. 2007;27(6):381-96.

**Stephens JM**, **Botteman MF**, Hay JW. Economic impact of antidiabetic medications and glycemc control on managed care organizations: a review of the literature. *J Manag Care Pharm*. 2006 Mar;12(2):130-42.

**van Gestel A**, Bakker J, Veraart CP, van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. *Crit Care*. 2004 Aug;8(4):R153-62. Epub 2004 May 14.





## 3 Database analysis

### 3.1 Chart review

**Chirikov VV**, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013-2016. *Adv Ther*. 2018 Jul;35(7):1087-1102. doi: 10.1007/s12325-018-0721-1. Epub 2018 Jun 9.

Zagadailov EA, **Corman S**, **Chirikov V**, **Johnson C**, Macahilig C, Seal B, Dalal MR, Bröckelmann PJ, Illidge T. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. *Leuk Lymphoma*. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.

Bröckelmann PJ, Zagadailov EA, **Corman SL**, **Chirikov V**, **Johnson C**, Macahilig C, Seal B, Dalal MR, Illidge T. Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma who are Ineligible for Autologous Stem Cell Transplant: A Germany and UK Retrospective Study. *Eur J Haematol*. 2017 Sep 26. doi: 10.1111/ejh.12973.

Moghnieh R, Alothman AF, Althaqafi AO, Matar MJ, Alenazi TH, Farahat F, **Corman SL**, **Solem CT**, Raghubir N, Macahilig C, **Stephens JM**. Epidemiology and outcome of invasive fungal infections and methicillin-resistant *Staphylococcus aureus* (MRSA) pneumonia and complicated skin and soft tissue infections (cSSTI) in Lebanon and Saudi Arabia. *J Infect Public Health*. 2017 May 6. pii: S1876-0341(17)30048-5. doi: 10.1016/j.jiph.2017.01.013.

Alothman AF, Althaqafi AO, Matar MJ, Moghnieh R, Alenazi TH, Farahat FM, **Corman S**, **Solem CT**, Raghubir N, Macahilig C, Charbonneau C, **Stephens JM**. Burden and treatment patterns of invasive fungal infections in hospitalized patients in the Middle East: real-world data from Saudi Arabia and Lebanon. *Infect Drug Resist*. 2017 Feb;10:35-41. doi: 10.2147/IDR.S97413.

Althaqafi AO, Matar MJ, Moghnieh R, Alothman AF, Alenazi TH, Farahat F, **Corman S**, **Solem CT**, Raghubir N, Macahilig C, Haider S, **Stephens JM**. Burden of methicillin-resistant *Staphylococcus aureus* pneumonia among hospitalized patients in Lebanon and Saudi Arabia. *Infect Drug Resist*. 2017 Feb;10:49-55. doi: 10.2147/IDR.S97416.

**Solem CT**, Patel H, **Mehta S**, Mody R, Macahilig C, **Gao X**. Treatment Patterns, Symptom Reduction, Quality of Life, and Resource Use Associated with Lubiprostone in Irritable Bowel Syndrome Constipation Subtype. *Curr Med Res Opin*. 2016 May;32(5):899-905. doi: 10.1185/03007995.2016.1150262.

Emery P, **Solem C**, **Majer I**, Cappelleri JC, Tarallo M.A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. *Rheumatol Int*. 2015 Nov;35(11):1837-49.

Dryden M, Baguneid M, Eckmann C, **Corman S**, **Stephens J**, **Solem C**, Li J, Charbonneau C, Baillon-Plot N, Haider S. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. *Clin Microbiol Infect*. 2015 Sep;21 Suppl 2:S27-32.

Eckmann C, Nathwani D, Lawson W, **Corman S**, **Solem C**, **Stephens J**, Macahilig C, Li J, Charbonneau C, Baillon-Plot N, Haider S. Comparison of vancomycin and linezolid in patients with peripheral vascular disease and, or diabetes in an



observational European study of complicated skin and soft tissue infections due to methicillin resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 2015 Sep;21 Suppl 2:S33-9.

Lawson W, Nathwani D, Eckmann C, **Corman S**, **Stephens J**, **Solem C**, Macahilig C, Li J, Baillon-Plot N, Charbonneau C, Haider S. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 2015 Sep;21 Suppl 2:S40-6.

Nathwani D, Lawson W, Dryden M, **Stephens J**, **Corman S**, **Solem C**, Li J, Charbonneau C, Baillon-Plot N, Haider S, Eckmann C. Implementing criteria-based early switch/early discharge programmes: a European perspective. *Clin Microbiol Infect.* 2015 Sep;21 Suppl 2:S47-55.

El Houfi A, Javed N, **Solem CT**, Macahilig C, **Stephens JM**, Raghur N, Chambers R, Li JZ, Haider S. Early-switch/early-discharge opportunities for hospitalized patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft tissue infections: proof of concept in the United Arab Emirates. *Infect Drug Resist.* 2015 Jun 18;8:173-9.

**Wan Y**, **Corman S**, **Gao X**, **Liu S**, Patel H, Mody R. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. *Am Health Drug Benefits.* 2015 Apr;8(2):93-102.

Nathwani D, Eckmann C, Lawson W, **Stephens JM**, Macahilig C, **Solem CT**, Simoneau D, Chambers R, Li JZ, Haider S. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft tissue infections. *Clin Microbiol Infect.* 2014 Oct;20(10):993-1000.

Nathwani D, Eckmann C, Lawson W, **Solem CT**, **Corman S**, **Stephens JM**, Macahilig C, Simoneau D, Chambers R, Li JZ, Haider S. Influence of real-world characteristics on outcomes for patients with methicillin-resistant *Staphylococcal* skin and soft tissue infections: a multi-country medical chart review in Europe. *BMC Infect Dis.* 2014 Sep 2;14:476.

**Solem CT**, Sun SX, **Liu S**, Macahilig C, Katyal M, **Gao X**, Shorr AF. Comparison of disease-severity measures within severe and very severe COPD patients: results from a nationally representative chart review and patient survey. *Int J Chron Obstruct Pulmon Dis.* 2014 Sep 23;9:991-8.

Turpin RS, **Solem C**, Pontes-Arruda A, Sanon M, **Mehta S**, Xiaoping Liu F, **Botteman M**. The impact of parenteral nutrition preparation on bloodstream infection risk and costs. *Eur J Clin Nutr.* 2014 Aug;68(8):953-8.

Eckmann C, Lawson W, Nathwani D, **Solem CT**, **Stephens JM**, Macahilig C, Simoneau D, Hajek P, Charbonneau C, Chambers R, Li JZ, Haider S. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*: a plea for implementation of early switch and early discharge criteria. *Int J Antimicrob Agents.* 2014 Jul;44(1):56-64.

**Solem C**, Mody R, **Stephens J**, Macahilig C, **Gao X**. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence. *J Am Pharm Assoc (2003).* 2014 Mar-Apr;54(2):144-53.

**Solem CT**, Sun SX, **Sudharshan L**, Macahilig C, Katyal M, **Gao X**. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2013;8:641-52.



Neufeld EJ, Recht M, Sabio H, Saxena K, **Solem CT**, Pickard AS, Gut RZ and Cooper DL. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. *Value Health*. 2012 Sep-Oct;15(6):916-25.

**Gao X, Stephens JM, Carter JA**, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. *Expert Rev Pharmacoecon Outcomes Res*. 2012 Jun;12(3):335-43.

Young G, **Solem CT**, Hoffman K, Kabawat J, Pickard AS, Gut RZ and Cooper DL. Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). *J Blood Med*. 2012;3:131-8.

### 3.2 Clinical Trial

Cortes J, Pérez-García J, Whiting S, **Wan Y, Solem C**, Tai MH, Margunato-Debay S, Ko A, Fandi A, **Botteman M**. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. *Clin Breast Cancer*. 2018 Mar 30. pii: S1526-8209(17)30778-4. doi: 10.1016/j.clbc.2018.03.014. [Epub ahead of print]

Pelzer U, Blanc J, Melisi D3, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, **Wan Y, Solem CT, Botteman MF**, Yang Y, de Jong FA, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. *Br J Cancer*. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67.

Rello J, Nieto M, Solé-Violán J, **Wan Y, Gao X, Solem CT**, De Salas-Cansado M, Mesa F, Charbonneau C, Chastre J. Nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective. *Med Intensiva*. 2016 November; 40(8): 474-482. doi: 10.1016/j.medin.2016.01.007.

**Solem CT**, Vera-Llonch M, **Liu S, Botteman M**, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. *Health Qual Life Outcomes*. 2016 Apr 21;14:63. doi: 10.1186/s12955-016-0465-z.b.

**Leshner B, Gao X**, Chen Y, Liu Z. Methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia: role of linezolid in the People's Republic of China. *Clinicoecon Outcomes Res*. 2016 Mar 24;8:63-72. doi: 10.2147/CEOR.S91985. eCollection 2016.

Lopez JM, Macomson B, **Ektare V, Patel D, Botteman M**. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus. *Am Health Drug Benefits*. 2015 Sep;8(6):309-18.

Wyke S, Hunt K, Gray CM, **Fenwick E**, Bunn C, Donnan PT, Rauchhaus P, Mutrie N, Anderson AS, Boyer N, Brady A, Grieve E, White A, Ferrell C, Hindle E, Treweek S. Football Fans in Training (FFIT): a randomized controlled trial of a gender-sensitised weight loss and healthy living programme for men. *Public Health Research*. 2015, 3 (2).

Cooper S, Morrison J, Allan L, McConnachie A, Greenlaw N, Melville C, Baltzer M, McArthur L, Lammie C, Martin G, Grieve E, **Fenwick E**. Practice nurse health checks for adults with intellectual disabilities: a cluster-design, randomised controlled trial. *The Lancet Psychiatry*. 2014, 1 (7): 511-521.



Furze G, Cox H, Morton V, **Chuang LH**, Lewin RJ, Nelson P, Carty R, Norris H, Patel N and Elton P. Randomized controlled trial of a lay-facilitated angina management programme. *J Adv Nurs*. 2012 Oct;68(10):2267-79.

**Chuang LH**, Soares MO, Tilbrook H, Cox H, Hewitt CE, Aplin J, Semlyen A, Trehwela A, I Watt, DJ Torgerson. A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation. *Spine (Phila Pa 1976)*. 2012 Aug 15; 37(18):1593-601.

Watson JM, Kang'ombe AR, Soares MO, **Chuang LH**, Worthy G, Bland JM, Iglesias C, Cullum N, Torgerson D, Nelson EA and Ven USIIT. Use of weekly, low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trial. *BMJ*. 2011 Mar 8; 342:d1092. doi: 10.1136/bmj.d1092.

Cox H, Tilbrook H, Aplin J, **Chuang LH**, Hewitt C, Jayakody S, Semlyen A, Soares MO, Torgerson D, Trehwela A, Watt I and Worthy G. A pragmatic multi-centred randomised controlled trial of yoga for chronic low back pain: trial protocol. *Complement Ther Clin Pract*. 2010 May;16(2):76-80.

### 3.3 Database Analysis

**Chirikov VV, Shah R, Kwon Y, Patel D**. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. *Ophthalmic Epidemiol*. 2018 Sep 10:1-20. doi: 10.1080/09286586.2018.1513042. [Epub ahead of print]

**Joshi N, Hensen M, Patel S, Xu W, Lasch K**, Stolk E. Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study. *Pharmacoeconomics*. 2018 Aug 23. doi: 10.1007/s40273-018-0704-8. [Epub ahead of print]

Young R, Mainwaring P, Clingan P, Parnis FX, Asghari G, Beale P, **Aly A, Botteman M**, Romano A, Ferrara S, Margunato-Debay S, Harris M. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. *Asia Pac J Clin Oncol*. 2018 Jun 22. doi: 10.1111/ajco.12999. [Epub ahead of print]

Hirsh V, Wan Y, Lin FJ, Margunato-Debay S, Ong TJ, **Botteman M**, Langer C. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. *Clin Lung Cancer*. 2018 Sep;19(5):401-409.e4. doi: 10.1016/j.clc.2018.04.023. Epub 2018 May 7.

Bangalore S, **Shah R**, Pappadopulos E, **Deshpande CG, Shelbaya A**, Prieto R, **Stephens J**, McIntyre RS. Cardiovascular Hazards of Insufficient Treatment of Depression Among Patients with Known Cardiovascular Disease: A Propensity Score Adjusted Analysis: Bangalore et al, CVD Hazards of Insufficient Depression Treatment. *Eur Heart J Qual Care Clin Outcomes*. 2018 Jun 11. doi: 10.1093/ehjqcco/qcy023. [Epub ahead of print]

Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora 9, Fraňková H, Campioni M, DeCosta L, **Treur M**, Gonzalez-McQuire S, **Bouwmeester W**. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. *Clin Lymphoma Myeloma Leuk*. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17.



**Deshpande CG**, Kogut S, Willey C. Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. *J Manag Care Spec Pharm*. 2018 May;24(5):430-439. doi: 10.18553/jmcp.2018.24.5.430.

**Serrano D**, Atzinger CB, **Botteman MF**. Understanding the disease course and therapeutic benefit of tafamidis across real-world studies of hereditary transthyretin amyloidosis with polyneuropathy: A proof of concept for integrative data analytic approaches. *Neurol Ther*. 2018 Jun;7(1):141-154. doi: 10.1007/s40120-018-0096-x. Epub 2018 Apr 2.

**Corman S**, **Shah N**, Dagenais S. Medication, equipment, and supply costs for common interventions providing extended post-surgical analgesia following total knee arthroplasty in US hospitals. *J Med Econ*. 2018 Jan;21(1):11-18. doi: 10.1080/13696998.2017.1371031. Epub 2017 Sep 18.

**Jiang S**, Hill K, **Patel D1**, Waldeck AR, **Botteman M**, **Aly A**, Norden AD. Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients. *J Med Econ*. 2017 Dec;20(12):1237-1243. doi: 10.1080/13696998.2017.1364258. Epub 2017 Aug 16.

Wilke T, Mueller S, Lee SC, **Majer I**, **Heisen M**. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. *BMC Musculoskelet Disord*. 2017 Aug 2;18(1):332. doi: 10.1186/s12891-017-1684-0.

Keeping ST, **Tempest MJ**, **Stephens SJ**, **Carroll SM**, Simcock R, Jones TM, Shaw R. The Cost of Oropharyngeal Cancer in England: a Retrospective Hospital Data Analysis. *Clin Otolaryngol*. 2018 Feb;43(1):223-229. doi: 10.1111/coa.12944. Epub 2017 Aug 14

**Atzinger CB**, Guo JJ. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends. *Am Health Drug Benefits*. 2017 Feb;10(1):27-36.

Sajatovic M, Ng-Mak D, **Solem CT**, **Lin FJ**, Rajagopalan K, Loebel A. Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis. *Ther Adv Psychopharmacol*. 2016 December; 6(6): 355-368. doi: 10.1177/2045125316672135.

**Solem CT**, Shelbaya A, **Wan Y**, **Deshpande CG**, Alvir J, Pappadopulos E.. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. *Neuropsychiatr Dis Treat*. 2016 October; 12: 2755-2764. eCollection 2016.

Wilke T, Mueller S, Groth A, Berg B, Hammar N, Tsai K, Fuchs A, **Stephens S**, Maywald U. Effectiveness of sulphonylureas in the [therapy of diabetes mellitus type 2 patients: an observational cohort study](#). *Journal of Diabetes & Metabolic Disorders*. 2016 Aug 2;15:28. doi: 10.1186/s40200-016-0251-9. eCollection 2015.

Rello J, Nieto M, Solé-Violán J, **Wan Y**, **Gao X**, **Solem CT**, De Salas-Cansado M, Mesa F, Charbonneau C, Chastre J. Nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective. *Med Intensiva*. 2016 Apr 6. pii: S0210-5691(16)00045-0. doi: 10.1016/j.medin.2016.01.007



Keeping ST, **Tempest MJ**, **Stephens SJ**, **Carroll SM**, Sangar VK Penile cancer treatment costs in England. BMC Public Health. 2015 Dec 29;15(1):1305. doi: 10.1186/s12889-015-2669-2.

Wilke T, Boettger B, Berg B, Groth A, Mueller S, **Botteman M**, Yu S, Fuchs A, Maywald U. Epidemiology of urinary tract infections in type 2 diabetes mellitus patients: An analysis based on a large sample of 456,586 German T2DM patients. J Diabetes Complications. 2015 Nov-Dec;29(8):1015-23

**Wan Y**, Sun SX, **Corman S**, Huang X, **Gao X**, Shorr AF. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. Int J Chron Obstruct Pulmon Dis. 2015 Oct 7;10:2127-36. doi: 10.2147/COPD.S80106.

Lopez JM1, Macomson B2, **Ektare V3**, **Patel D4**, **Botteman M5**. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus. Am Health Drug Benefits. 2015 Sep;8(6):309-18.

El Houfi A, Javed N, **Solem CT**, Macahilig C, **Stephens JM**, Raghubir N, Chambers R, Li JZ, Haider S. Early switch/early - discharge opportunities for hospitalized patients with methicillin-resistant staphylococcus aureus complicated skin and soft tissue infections: proof of concept in the United Arab Emirates. Infect Drug Resist. 2015 Jun;8:173-9.

Langer CJ, Hirsh V, Okamoto I, **Lin FJ**, **Wan Y**, Whiting S, Ong TJ, Renschler MF, **Botteman MF**. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel. Br J Cancer. 2015 Jun 30;113(1):20-9.

**Charokopou M**, **Majer IM**, Raad Jd, **Broekhuizen S**, Postma M, **Heeg B**. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013. Value Health. 2015 Mar;18(2):284-91.

Palmer P, **Ji X**, **Stephens J**. Cost of opioid intravenous patient-controlled analgesia: results from a hospital database analysis and literature assessment. Clinicoecon Outcomes Res. 2014 Jun;6:311-8.

**Solem CT**, **Snedecor SJ**, **Khachatryan A**, Nedrow K, Tawadrous M, Chambers R, Haider S, Simpson K. Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One. 2014 May 27;9(5):e98152. doi: 10.1371/journal.pone.0098152. eCollection 2014.

Ul-Haq Z, Mackay D, **Fenwick E**, Pell J. Association between body mass index and mental health among Scottish adult population: a cross-sectional study of 37,272 participants. Psychological Medicine. 2014, 44 (10): 2231-2240.

Hunt K, Wyke S, Gray CM, Anderson AS, Brady A, Bunn C, Donnan PT, **Fenwick E**, Grieve E, Leishman J, Miller E, Mutrie N, Rauchhaus P, White A, Treweek S. A gender-sensitised weight loss and healthy living programme for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): A pragmatic randomised controlled trial. The Lancet. 2014, 383 (9924): 1211-1221.

**Xu W** and Van de Ven WP. The level of consumer information about health insurance in Nanjing, China. Int J Health Plann Manage. 2014 Apr-Jun;29(2):175-96.

**Baeten S**, Van Ourti T, van Doorslaer E. Rising inequalities in income and health in China: who is left behind? J Health Econ. 2013 Dec;32(6):1214-29.



**Gu NY, Botteman MF**, Gerber RA, **Ji X, Postema R, Wan Y**, Sianos G, Anthony I, Cappelleri JC, Szczypa P, **van Hout B**. Eliciting health state utilities for Dupuytren's contracture using a discrete choice experiment. *Acta Orthop*. 2013 Dec;84(6):571-8.

Saavedra JM, Boguniewicz M, Chamlin S, Lake A, Nedorost S, Czerkies LA, **Patel V, Botteman MF** and **Horodniceanu EG**. Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States. *J Pediatr*. 2013 Dec;163(6):1747-53.

Varni JW, Curtis BH, Abetz LN, **Lasch KE**, Piau EC and Zeytoonjian AA. Content validity of the PedsQL 3.2 Diabetes Module in newly diagnosed patients with Type 1 diabetes mellitus ages 8-45. *Qual Life Res*. 2013 Oct;22(8):2169-81.

**Wan Y, Gao X, Mehta S**, Wang Z, Faria C, Schwartzberg L. Indirect costs associated with metastatic breast cancer. *J Med Econ*. 2013 Oct;16(10):1169-78.

**Gao X**, Marks DI, Schlamm HT, **Ji X, Stephens JM**, Tarallo M. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant. *J Med Econ*. 2013 Aug;16(8):1061-70.

Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G and **van Hout B**. A Comparison of Alternative Variants of the Lead and Lag Time TTO. *Health Econ*. 2013 May;22(5):517-32.

Baddley JW, **Stephens JM, Ji X, Gao X**, Schlamm HT and Tarallo M. Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. *BMC Infect Dis*. 2013 Jan 23;13:29.

Abudagga A, Sun SX, Tan H and **Solem CT**. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population. *J Med Econ*. 2013;16(3):421-9.

**Solem CT**, Lee TA, Joo MJ, Lambert BL, Walton SM and Pickard AS. Complexity of medication use in newly diagnosed chronic obstructive pulmonary disease patients. *Am J Geriatr Pharmacother*. 2012 Apr.

Rowen D, Mulhern B, Banerjee S, **van Hout B**, Young TA, Knapp M, Smith SC, Lamping DL and Brazier JE. Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. *Value Health*. 2012 Mar-Apr.

**Gu NY**, Bell C, **Botteman MF, Ji X, Carter JA, van Hout B**. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. *Patient*. 2012;5(3):185-97.

**Chuang LH** and Whitehead SJ. Mapping for economic evaluation. *Br Med Bull*. 2012;101:1-15.

Gould JC, Kent KC, **Wan Y**, Rajamanickam V, Levenson G, Campos GM. Perioperative safety and volume: outcomes relationships in bariatric surgery: a study of 32,000 patients. *J Am Coll Surg*. 2011 Dec;213(6):771-7.

**Majer IM**, Nusselder WJ, Mackenbach JP, Klijs B and van Baal PH. Mortality risk associated with disability: a population-based record linkage study. *Am J Public Health*. 2011 Dec;101(12):e9-15.



Leissinger C, Cooper DL, **Solem CT** and HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. *Haemophilia*. 2011 Nov;17(6):884-9.

Yu XM, **Wan Y**, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. *Ann Surg*. 2011 Oct;254(4):653-60.

Joshi AD, **Patel DA** and Holdford DA. Media coverage of off-label promotion: a content analysis of US newspapers. *Res Social Adm Pharm*. 2011 Sep;7(3):257-71.

Greenblatt DY, Kelly KJ, Rajamanickam V, **Wan Y**, Hanson T, Rettammel R, Winslow ER, Cho CS, Weber SM. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. *Ann Surg Oncol*. 2011 Aug;18(8):2126-35. Epub 2011 Feb 20.

**Patel DA**, Holdford D, Edwards E, Carroll N. Economic Burden of Food Allergy and Anaphylaxis in the US. *Journal of Allergy and Clinical Immunology*; 2011 Jul; 128(1): 110-115.

Raaijmakers MA, Posthumus JA, **van Hout BA**, van Engeland H and Matthys W. Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behaviour. *Prev Sci*. 2011 Jun;12(2):192-200.

Kluza E, **Heisen M**, Schmid S, van der Schaft DW, Schiffelers RM, Storm G, ter Haar Romeny BM, Strijkers GJ and Nicolay K. Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. *Angiogenesis*. 2011 May;14(2):143-53.

Farooq U, Guo X, **Chuang LH**, Fang H, Zhuang G and Xia C. Measuring health-related quality of life in Kashin-Beck disease using EQ-5D. *Qual Life Res*. 2011 Apr;20(3):425-9.

Cohen DJ, **Van Hout B**, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP, Synergy between PCIwT and Cardiac Surgery I. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. *N Engl J Med*. 2011 Mar 17;364(11):1016-26.

Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, **van Hout BA**. Survival after transfusion in the Netherlands. *Vox Sang*. 2011 Feb; 100(2):196-203.

Kelly KJ, Greenblatt DY, **Wan Y**, Rettammel RJ, Winslow E, Cho CS, Weber SM. Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. *J Gastrointest Surg*. 2011 Feb;15(2):250-9, discussion 259-61. Epub 2010 Dec 15.

**Chuang LH** and Kind P. The effect of health state selection on the valuation of EQ-5D. *Med Decis Making*. 2011 Jan-Feb;31(1):186-94.

**Patel D**, Joshi A, Holdford D and Saxena K. Content Analysis of Off-label Drug Use: Reporting Print Media Coverage. *Drug Inf J*. 2011; 45:787-796.

**Patel DA**, **Gao X**, **Stephens JM**, Forshag MS, Tarallo M. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. *J Med Econ*. 2011;14(2):227-37.





Huang X, [Gu NY](#), Fox KM, Harrison DJ, Globe D. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. *Curr Med Res Opin.* 2010; 26(7): 1637-45.

Lang HC, [Chuang L](#), Shun SC, Hsieh CL and Lan CF. Validation of EQ-5D in patients with cervical cancer in Taiwan. *Support Care Cancer.* 2010 Oct;18(10):1279-86.

Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, [van Hout BA](#). The PROTON study: profiles of blood product transfusion recipients in the Netherlands. *Vox Sang.* 2010 Jul; 99(1):54-64.

[Snedecor SJ](#), [Botteman MF](#), Schaefer K, Sarocco P, Barry N, Pickard AS. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. *J Ment Health Policy Econ.* 2010 Mar;13(1):27-35.

Brubaker L, Fanning K, [Goldberg EL](#), Benner JS, Trocio JN, Bavendam T and Jumadilova Z. Predictors of discontinuing overactive bladder medications. *BJU Int.* 2010; 105(9):1283-90.

Lavsa SM, Fabian TJ, Saul MI, [Corman SL](#), Coley KC. Influence of medications and diagnoses on fall risk in psychiatric inpatients. *Am J Health-Syst Pharm* 2010;67:1274-80.

Schonder KS, [Corman SL](#), Hung WY. Early risk factors for persistent anemia after kidney transplant. *Pharmacotherapy* 2010;30:1214-20



## 4 Meta-Analysis

Chiorean EG, Von Hoff D, Wan Y, Margunato-Debay S, **Botteman M**, Goldstein D. Performance status dynamics during treatment with nab-paclitaxel plus gemminimcitabine versus gemcitabine alone for metastatic pancreatic cancer. *Cancer Manag Res.* 2018 May 31;10:1389-1396. doi: 10.2147/CMAR.S163475. eCollection 2018.

Aletaha D, **Snedecor SJ**, **Ektare V**, **Xue M**, **Bao Y**, Garg V. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor- $\alpha$  inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. *Clinicoecon Outcomes Res.* 2017 Jul 28;9:451-458. doi: 10.2147/CEOR.S136327. eCollection 2017.

Lishman H, Aylin P, Alividza V, Castro-Sanchez E, **Chatterjee A**, Mariano V, Johnson AP, Jeraj S, Costelloe C. Investigating the burden of antibiotic resistance in ethnic minority groups in high-income countries: protocol for a systematic review and meta-analysis. *Syst Rev.* 2017 Dec 11;6(1):251. doi: 10.1186/s13643-017-0654-9.

van Nooten F, **Treur M**, **Pantiri K**, Stoker M, **Charokopou M**. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis. *Clin Ther.* 2017 Apr;39(4):787-803.e18. doi: 10.1016/j.clinthera.2017.02.010.

Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, **Patel DA**, **Ektare V**, de Jong FA, Gill S. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. *Cancer treatment reviews.* 2016 November; : 142-147. doi: 10.1016/j.ctrv.2016.09.001.

**Majer I**, **van de Wetering G**, Polanyi Z, Krishna A, Gray E, Roy A. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. *Appl Health Econ Health Policy.* 2016 Aug 22.

Howlett C, **Snedecor SJ**, Landsburg D, Svoboda J, Chong E, Schuster S, Nasta S, Feldman T, Rago A, Walsh K, Weber WS, Goy A, Mato A. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. *Br J Haematol.* 2015 Aug;170(4):504-14.

**Majer IM**, Gaughran F, Sapin C, Beillat M, **Treur M**. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. *J Market Access Health Policy.* 2015;3(1):27208. doi:10.3402/jmahp.v3.27208.

**Patel DA**, **Snedecor SJ**, **Tang WY**, **Sudharshan L**, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, **Stephens J**, Nichols G., 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. *PLoS One.* 2014 Sep 4;9(9).

**Snedecor SJ**, **Sudharshan L**, Nedrow K, **Bhanegaonkar A**, Simpson KN, Haider S, Chambers R, Craig C, **Stephens J**., Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. *AIDS Res Hum Retroviruses.* 2014 Aug;30(8):753-68.



**Snedecor SJ, Sudharshan L**, Cappelleri JC, Sadosky A, Desai P, Jalundhwala Y, **Botteman M.**, Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions., *Int J Clin Pract.* 2014 Jul;68(7):900-18.

Snedecor S, **Sudharshan L**, Cappelleri J, Sadosky A, **Mehta S, Botteman M.** Systematic Review and Meta-Analysis of Pharmacological Therapies for Painful Diabetic Peripheral Neuropathy. *Pain Pract.* 2013 Mar 28.

Wu AW, Hanson KA, Harding G, Haider S, Tawadrous M, **Khachatryan A**, Pashos CL and Simpson KN. Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. *Health Qual Life Outcomes.* 2013 Mar 12;11:42.

**Gao X**, Wendling D, **Botteman MF, Carter JA**, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. *J Med Econ.* 2012;15(6):1054-63.

**Stephens J**, Carpiuc KT, **Botteman M.** The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis. *Int J Gen Med.* 2010 Apr 8; 3:31-6.

Carpiuc KT, Rosti G, Castagnetti F, **Treur M, Stephens J.** Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics. *OncoTargets and Therapy* 2010;3:205 – 210.

Logman JS, **Stephens JS, Heeg B**, Haider S, Cappelleri J, Nathwani D, Tice A, **van Hout BA.** Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. *Curr Med Res Opin* 2010; 26:1565–78.



## 5 Methodology and Policy

Deane K, [Delbecque L](#), Gorbenko O, Hamoir AM, Hoos A, Nafria B, Pakarinen C, Sargeant I, Richards DP, Skovlund SE, Brooke N. Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative. *BMJ Innovations*. 2019 March 3. 10.1136/bmjinnov-2018-000317

Rowen D, Azzabi Zouraq I, Chevrou-Severac H, [van Hout B](#). International Regulations and Recommendations for Utility Data for Health Technology Assessment. *Pharmacoeconomics*. 2017 Oct 19. doi: 10.1007/s40273-017-0544-y.

Waldeck AR, [Botteman MF](#), White RE, [van Hout BA](#). The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making. *J Manag Care Spec Pharm*. 2017 Jun;23(6-a Suppl):S6-S12. doi: 10.18553/jmcp.2017.23.6-a.s6.

Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, [Botteman M](#), Busschbach J. Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. *Value Health*. 2017 Jan;20(1):18-27. doi: 10.1016/j.jval.2016.11.006.

Miller L, Steinmetz Pater K, [Corman S](#). The role of clinical decision support in pharmacist response to drug-interaction alerts. *Res Social Adm Pharm*. 2015 May-Jun;11(3):480-6.

Skledar SJ, [Corman SL](#), Smitherman T. Addressing innovative off-label medication use at an academic medical center. *Am J Health Syst Pharm* 2015 Mar;72(6):469-77.

Wynants L, [Bouwmeester W](#), Moons KG, Moerbeek M, Timmerman D, Van Huffel S, Van Calster B, Vergouwe Y. A simulation study of sample size demonstrated the importance of the number of events per variable to develop prediction models in clustered data. *J Clin Epidemiol*. 2015 Dec;68(12):1406-14. doi: 10.1016/j.jclinepi.2015.02.002. Epub 2015 Feb 14.

[Patel DA](#), [Snedecor SJ](#), [Tang WY](#), [Sudharshan L](#), Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, [Stephens J](#), Nichols G., 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. *PLoS One*. 2014 Sep;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014.

[Heeg BM](#), [van Hout BA](#). Assessing uncertainties surrounding combined endpoints for use in economic models. *Med Decis Making*. 2014 Apr;34(3):300-10.

[Xu W](#) and Van de Ven WP. The level of consumer information about health insurance in Nanjing, China. *Int J Health Plann Manage*. 2014 Apr-Jun;29(2):175-96.

[Xu W](#) and van de Ven WP. Consumer choice among Mutual Healthcare Purchasers: A feasible option for China? *Soc Sci Med*. 2013 Nov;96:277-84.

[Majer IM](#), Stevens R, Nusselder WJ, Mackenbach JP and van Baal PH. Modeling and Forecasting Health Expectancy: Theoretical Framework and Application. *Demography*. 2013 Apr;50(2):673-97.



Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G and **van Hout B**. A Comparison of Alternative Variants of the Lead and Lag Time TTO. *Health Econ*. 2013 May;22(5):517-32.

de Meijer CA, **Majer IM**, Koopmanschap MA and van Baal PH. Forecasting lifetime and aggregate long-term care spending: accounting for changing disability patterns. *Med Care*. 2012 Aug;50(8):722-9.

**van Hout B**, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P and Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health*. 2012 Jul-Aug;15(5):708-15.

**Chuang LH** and Whitehead SJ. Mapping for economic evaluation. *Br Med Bull*. 2012; 101:1-15.

**Stephens JM**, Handke B and Doshi JA. International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research? *Comparative Effectiveness Research*. 2012; 2:29-44.

**Majer IM**, Nusselder WJ, Mackenbach JP, Klijs B and van Baal PH. Mortality risk associated with disability: a population-based record linkage study. *Am J Public Health*. 2011 Dec;101(12):e9-15.

Joshi AD, **Patel DA** and Holdford DA. Media coverage of off-label promotion: a content analysis of US newspapers. *Res Social Adm Pharm*. 2011 Sep;7(3):257-71.

**Chuang LH**, Soares MO, Watson JM, Bland JM, Cullum N, Iglesias C, Kang'ombe AR, Torgerson D, Nelson EA and Ven USIII. Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers. *Br J Surg*. 2011 Aug;98(8):1099-106.

**Xu W**, Sheiman I, van de Ven WP and Zhang W. Prospects for regulated competition in the health care system: what can China learn from Russia's experience? *Health Policy Plan*. 2011 May;26(3):199-209.

**Chuang LH** and Kind P. The effect of health state selection on the valuation of EQ-5D. *Med Decis Making*. 2011 Jan-Feb;31(1):186-94.

**Majer IM**, Nusselder WJ, Mackenbach JP and Kunst AE. Socioeconomic inequalities in life and health expectancies around official retirement age in 10 Western-European countries. *J Epidemiol Community Health*. 2011; 65(11):972-9.

**Patel D**, Joshi A, Holdford D and Saxena K. Content Analysis of Off-label Drug Use: Reporting Print Media Coverage. *Drug Inf J*. 2011; 45(6):787-796.

**Xu W**, van de Ven WP and Dong CH. Regulated competition – What can China learn from the Netherlands. *Chinese journal of health policy*. 2011; 4:65-70.

**Lasch KE**, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, Crawford B and Rosa K. PRO development: rigorous qualitative research as the crucial foundation. *Qual Life Res*. 2010 Oct;19(8):1087-96.



Logman JF, **Heeg BM**, **Botteman MF**, Kaura S, **van Hout BA**. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. *Ann Oncol*. 2010 Jul;21(7):1529-36. doi: 10.1093/annonc/mdp560. Epub 2009 Dec 2.

**Botteman M**. Health economics of insomnia therapy: implications for policy. *Sleep Med*. 2009 Sep;10 Suppl 1:S22-5. doi: 10.1016/j.sleep.2009.07.001. Epub 2009 Jul 31.

Thurston SJ, **Craig D**, Wilson P, Drummond MF. Increasing decision-makers' access to economic evaluations: alternative methods of communicating the information. *Int J Technol Assess Health Care*. 2008 Spring;24(2):151-7. doi: 10.1017/S0266462308080215.

**Heeg B**, Damen J, **Van Hout B**. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. *Pharmacoeconomics*. 2007;25(12):1063-82.



## 6 Patient-Reported Outcomes

- Willich SN, Chuang LH, [van Hout B](#), Gumbs P, Jimenez D, [Kroep S](#), Bauersachs R, Monreal M, Agnelli G, Cohen A. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. *Thromb Res.* 2018 Feb 16;170:181-191. doi: 10.1016/j.thromres.2018.02.009. [Epub ahead of print]
- Chuang LH, [van Hout B](#), Cohen AT, Gumbs PD, [Kroep S](#), Bauersachs R, Gitt A, Monreal M, Willich SN, Agnelli G. Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. *Thromb Res.* 2018 Aug 4;170:165-174. doi: 10.1016/j.thromres.2018.08.001. [Epub ahead of print]
- McDermott DF, [Shah R](#), Gupte-Singh K, Sabater J, [Luo L](#), [Botteman M](#), Rao S, Regan MM, Atkins M. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. *Qual Life Res.* 2018 Sep 6. doi: 10.1007/s11136-018-1984-3. [Epub ahead of print]
- Marcus J, [Lasch K](#), [Wan Y](#), Yang M, Hsu C, Merante D. An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain. *Pain Res Manag.* 2018 Jul 22;2018:2140420. doi: 10.1155/2018/2140420. eCollection 2018.
- Cheung WY, White MK, Bayliss MS, [Stroupe A](#), Lovley A, [King-Kallimanis BL](#), [Lasch K](#). Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. *Support Care Cancer.* 2018 Jun 23. doi: 10.1007/s00520-018-4316-9. [Epub ahead of print]
- Cheung WY, Bayliss MS, White MK, [Stroupe A](#), Lovley A, [King-Kallimanis BL](#), [Lasch K](#). Humanistic burden of disease for patients with advanced melanoma in Canada. *Support Care Cancer.* 2018 Jun;26(6):1985-1991. doi: 10.1007/s00520-017-4025-9. Epub 2018 Jan 10.
- [Horodniceanu EG](#), Bal V, [Dhatt H](#), [Carter JA](#), Huang V, [Lasch K](#). Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy. *Health Qual Life Outcomes.* 2017 Jun 23;15(1):129. doi: 10.1186/s12955-017-0702-0.
- [Miskala PH](#). Development, Use, and Interpretation of Patient-Reported Outcomes for Clinical Decision Making in Ophthalmology. *JAMA Ophthalmol.* 2016 June; 134(6): 690-2. doi: 10.1001/jamaophthalmol.2016.0820.
- Delgado-Herrera L, [Lasch K](#), Popielnicki A, Nishida A, Arbuckle R, Banderas B, Zentner S, Gagainis I, Zeiher B. Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea. *Patient Relat Outcome Meas.* 2016 Jun 22;7:81-92. doi: 10.2147/PROM.S102647. eCollection 2016.
- Mercer SW, Fitzpatrick B, Guthrie B, [Fenwick E](#), Grieve E, Lawson K, Boyer N, McConnachie A, Lloyd SM, O'Brien R, Watt GCM, Wyke S. The CARE Plus study – a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised trial and cost-utility analysis. *BMC Medicine.* 2016. 14:88.



Mercioca-Bebber RL, Perreca A, King M, Macann A, Whale K, Soldati S, **Jacobs M**, Efficace F. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation. *Eur J Cancer*. 2016 Mar;56:144-61. doi: 10.1016/j.ejca.2015.12.025

**Lasch K**, Delgado-Herrera L, Tesler Waldman L, Kathleen R, Glen S, Lembo J A, Marqui P, Kothari S, Lademacher C, Gagains I, Z Bernhardt. Development of a new instrument to assess stool form and consistency in irritable bowel syndrome with diarrhea. *Gastroenterol Hepatol Open Access*. 2016 Jan. 4(1):00084. DOI: 10.15406/ghoa.2016.04.00084

Hillen, M.A., Koning, C.C.E., Wilmlink, J.W., Klinkenbijn, J.H.G., Eddes, E.H., **King-Kallimanis, B. L.**, de Haes, J.C.J.M., & Smets, E.M.A. Assessing cancer patients' trust in their oncologist: development and validation of the Trust in Oncologist Scale (TIOS). *Supportive Care in Cancer*. 2014 20: 1781-1795

Reni M, **Wan Y**, **Solem C**, Whiting S, **Ji X**, **Botteman M**. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. *J Med Econ*. 2014;17(5):338-46.

**Solem CT**, Vera LLonch M, **Liu S**, **Botteman MF**, **Lasch K**, Rodriguez S, Castiglione B. Responsiveness Of The Eq-5d Index And Visual Analog Scale To Changes In Lung Function In Patients With Cystic Fibrosis. *Value in Health*, 2014; Volume 17, Issue 3, Page A178

Recht M, Neufeld EJ, Sharma VR, **Solem CT**, Pickard AS, Gut RZ, Cooper DL. Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from The Dosing Observational Study in Hemophilia (DOSE). *Value Health*. 2014 Sep;17(6):744-8.

Marquis P, **Lasch KE**, Delgado-Herrera L, Kothari S, Lembo A, Lademacher C, Spears G, Nishida A, Tesler WL, Piauxt E, Rosa K, Zeiher B. Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. *Clin Transl Gastroenterol*. 2014 Jun 26;5:e59. doi: 10.1038/ctg.2014.7.

Sexton, E., **King-Kallimanis B.L.**, Morgan, K., & McGee, H. Development of the Brief Ageing Perceptions Questionnaire (B-APQ): A confirmatory factor analysis approach to item reduction. *BMC Geriatr*. 2014 Apr 9;14:44

**Gu NY**, **Botteman MF**, Gerber RA, **Ji X**, **Postema R**, **Wan Y**, Sianos G, Anthony I, Cappelleri JC, Szczypa P, **van Hout B**. Eliciting health state utilities for Dupuytren's contracture using a discrete choice experiment. *Acta Orthop*. 2013 Dec;84(6):571-8.

**Lasch KE**, Hassan M, Endicott J, Piauxt-Luis EC, Locklear J, Fitz-Randolph M, Pathak S, Hwang S and Jernigan K. Development and content validity of a patient reported outcomes measure to assess symptoms of major depressive disorder. *BMC Psychiatry*. 2012 Apr 25;12:34.

Jolly M, Pickard AS, Sequeira W, Wallace DJ, **Solem CT**, Mikolaitis RA, Fogg L, Weisman MH, Block JA and Cash TF . A brief assessment tool for body image in systemic lupus erythematosus. *Body Image*. 2012 Mar;9(2):279-84.

Ben-Shlomo A, Sheppard MC, **Stephens JM**, Pulgar S and Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. *Pituitary*. 2011 Sep;14(3):284-94.





**Lasch KE**, Abraham L, Patrick J, Piault EC, Tully SE and Treglia M. Development of a next day functioning measure to assess the impact of sleep disturbance due to restless legs syndrome: the restless legs syndrome-next day impact questionnaire. *Sleep Med.* 2011 Sep;12(8):754-61.

Fourquet J, **Gao X**, Zavala D, Orengo JC, Abac S, Ruiz A, Laboy J and Flores I. Patients' report on how endometriosis affects health, work, and daily life. *Fertil Steril.* 2010 May 1;93(7):2424-8.

**Lasch KE**, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M, et al. PRO development: rigorous qualitative research as the crucial foundation. *Quality of Life Research*, 2010 19(8): 1087-1096.



## 7 Preference-Based and PRO Measures

Devlin NJ, Shah KK, Mulhern BJ, [Pantiri K](#), [van Hout B](#). A new method for valuing health: directly eliciting personal utility functions. *Eur J Health Econ*. 2018 Jul 20. doi: 10.1007/s10198-018-0993-z. [Epub ahead of print]

Ara R, Peasgood T, Mukuria C, Chevrou-Severac H, Rowen D, Azzabi-Zouraq I, Paisley S, Young T, [van Hout B](#), Brazier J. Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care. *Pharmacoeconomics*. 2017 Oct 19. doi: 10.1007/s40273-017-0543-z.

Delgado-Herrera L, [Lasch K](#), Zeiher B, Lembo AJ, Drossman DA, Banderas B, Rosa K, Lademacher C, Arbuckle R. Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. *Therap Adv Gastroenterol*. 2017 Sep;10(9):673-687. doi: 10.1177/1756283X17726018. Epub 2017 Aug 24.

Devlin NJ, Shah KK, Feng Y, Mulhern B, [van Hout B](#). Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Econ*. 2017 Aug 22. doi: 10.1002/hec.3564.

Feng Y, Devlin NJ, Shah KK, Mulhern B, [van Hout B](#). New methods for modelling EQ-5D-5L value sets: An application to English data. *Health Econ*. 2017 Aug 18. doi: 10.1002/hec.3560.

Tsai CF, Tsai PS, Liu CL, Lin YK, [Ling YL](#), Tseng IJ, Liao YM. Psychometric Evaluation of the Chinese Breast Cancer Prevention Trial Symptom Scale. *Cancer Nurs*. 2017 May 5. doi: 10.1097/NCC.0000000000000499.

[Heisen M](#), [Baeten SA](#), [Verheggen BG](#), Stoelzel M, Hakimi Z, Ridder A, van Maanen R, Stolk EA. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. *Curr Med Res Opin*. 2016 Feb 12:1-10.

Rowen D, Brazier J, [van Hout B](#). A comparison of methods for converting DCE values onto the full health-dead QALY scale. *Med Decis Making*. 2015 Apr;35(3):328-40.

Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, [van Hout B](#), Quik EH, Pickard AS, Xie F. Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. *Med Care*. 2014 Nov;52(11):935-43.

Oppe M, Devlin NJ, [van Hout B](#), Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. *Value Health*. 2014 Jun;17(4):445-53. doi: 10.1016/j.jval.2014.04.002.

[van Hout B](#), Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health*. 2012 Jul-Aug;15(5):708-15.

Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G, [van Hout B](#). A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO. *Health Econ*. 2012 Jun 19.



**Gu NY**, Bell C, **Botteman MF**, **Ji X**, **Carter JA**, **van Hout B**. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. *Patient*. 2012;5(3):185-97.

**Gu NY**, **Botteman MF**, **Ji X**, Bell CF, **Carter JA**, **van Hout B**. Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. *Health Qual Life Outcomes*. 2011 Dec 30;9:119.

Varni JW, Curtis BH, Abetz LN, **Lasch KE**, Piau EC and Zeytoonjian AA. Content validity of the PedsQL 3.2 Diabetes Module in newly diagnosed patients with Type 1 diabetes mellitus ages 8-45. *Qual Life Res*. 2013 Oct;22(8):2169-81.

**Lasch KE**, Abraham L, Patrick J, Piau EC, Tully SE, Treglia M. Development of a Next Day Functioning Measure to Assess the Impact of Sleep Disturbance Due to Restless Legs Syndrome (RLS): The Restless Legs Syndrome-Next Day Impact (RLS-NDI) Questionnaire, accepted for publication, *Sleep Medicine*, August 6, 2011 (available on line).

Scott JA, **Lasch K**, Barsevick A, Piau-Louis E. Patient-Reported Outcomes of Fatigue Consortium (PROOF-C). Patients' Experiences with Cancer-Related Fatigue: A Systematic Review and Synthesis of Qualitative Research, accepted for publication, *Oncology Nursing Forum*, 2011.

**Lasch K**, Marquis P, Vigneux M, Abetz L, Arnould B, Bayliss M et al. PRO development: rigorous qualitative research as the crucial foundation. *Qual Life Res* 2010.

**Lasch K**, Stokes J, Liepa AM, Meldahl M, Arnett L, Basch E. Drivers of Treatment Decision Following First-Line Therapy in Advanced Non-Small Cell Lung Cancer. *Support Care Cancer* 2010; 18(Suppl 3):S88-S89

**Gu NY**, Bell C, **Botteman M**, **van Hout B**. "Comparing the time tradeoff (TTO), the visual analogue scale (VAS) and the EQ-5D value-sets in patients treated with painful diabetic peripheral neuropathy (pDPN) or post-herpetic neuralgia (PHN). *Value in Health*. 2010; 13(3): A212.

**Gu NY**, Bell C, **Botteman M**, **van Hout B**. "Association between self-reported neuropathic pain severity and the EQ-5D in patients with painful diabetic peripheral neuropathy (pDPN) or post-herpetic neuralgia (PHN)" *Value in Health*. 2010; 13(3): A213.

**Thurston SJ**, Craig D, Wilson P, Drummond MF. Increasing decision-makers' access to economic evaluations: alternative methods of communicating the information. *Int J Technol Assess Health Care*. 2008 Spring;24(2):151-7. doi: 10.1017/S0266462308080215.



## 8 Other

Fishleder S, Gum AM, **King-Kallimanis BL**, Schonfeld L. Trajectories of depressive symptoms in community-dwelling older adults: A six-month longitudinal study with monthly assessment. *J Affect Disord.* 2016 Jul 1;198:171-7. doi: 10.1016/j.jad.2016.02.058. Epub 2016 Mar 10.

Vandigo J, Oloyede E, **Aly A**, Laird AL, **Cooke CE**, Mullins CD. Continuous patient engagement in cardiovascular disease comparative clinical effectiveness research. *Expert Rev Pharmacoecon Outcomes Res.* 2016 Mar 7

Kaye KS, **Patel DA**, **Stephens JM**, **Khachatryan A**, **Patel A**, Johnson K. Rising United States Hospital Admissions for Acute Bacterial Skin and Skin Structure Infections: Recent Trends and Economic Impact. *PLoS One.* 2015 Nov 24;10(11):e0143276. doi: 10.1371/journal.pone.0143276

**Leshner BA**, Liu Z, Chen Y, **Gao X**. Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital. *Clinicoecon Outcomes Res.* 2015 Oct 9;7:521-6.

Miller L, Steinmetz Pater K, **Corman S**. The role of clinical decision support in pharmacist response to drug-interaction alerts. *Res Social Adm Pharm.* 2015 May-Jun;11(3):480-6.

Rangan A, Handoll H, Brealey S, Jefferson L, Keding A, Martin BC, Goodchild L, **Chuang LH**, Hewitt C, Torgerson D; PROFHER Trial Collaborators. Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: the PROFHER randomized clinical trial. *JAMA.* 2015 Mar; 10;313(10).

Liu FX, **Gao X**, Inglese G, Chuengsaman P, Pecoits-Filho R, Yu A. A Global Overview of the Impact of Peritoneal Dialysis First or Favored Policies: An Opinion. *Perit Dial Int.* 2015 7-8;35(4):406-420.

Saavedra JM, Boguniewicz M, Chamlin S, Lake A, Nedorost S, Czerkies LA, **Patel V**, **Botteman MF** and **Horodniceanu EG**. Patterns of clinical management of atopic dermatitis in infants and toddlers: a survey of three physician specialties in the United States. *J Pediatr.* 2013 Dec;163(6):1747-53.

**Stephens JM**, Handke B and Doshi JA. International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research? *Comparative Effectiveness Research.* 2012; 2:29-44.

Pickard AS, Lee TA, **Solem CT**, Joo MJ, Schumock GT and Krishnan JA. Prioritizing comparative-effectiveness research topics via stakeholder involvement: an application in COPD. *Clin Pharmacol Ther.* 2011 Dec;90(6):888-92

**Patel DA**, Holdford DA, Edwards E and Carroll NV. Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. *J Allergy Clin Immunol.* 2011 Jul;128(1):110-115.e

**Xu W**, Sheiman I, van de Ven WP and Zhang W. Prospects for regulated competition in the health care system: what can China learn from Russia's experience? *Health Policy Plan.* 2011 May;26(3):199-209.

**Xu W**, van de Ven WP and Dong CH. Regulated competition – What can China learn from the Netherlands. *Chinese journal of health policy.* 2011; 4:65-70.

